Skip to main content

Table 2 Primary and secondary outcomes

From: High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study

Outcomes

Standard oxygen therapy

HFNO

unadjusted

IPTW

OR [IC95%]

p

OR [IC95%]

p

IMV—no (%)

46/62 (74%)

39/76 (51%)

0.37 [0.18–0.76]

0.007

0.31 [0.14–0.66]

0.002

Death at D28—no (%)

15/62 (24%)

9/76 (12%)

0.42 [0.17–1.04]

0.061

0.52 [0.2–1.34]

0.17

Death at D60—no (%)

16/62 (26%)

12/76 (16%)

0.54 [0.23–1.25]

0.15

0.75 [0.32–1.8]

0.52

Ventilator free days, days (IQR)

10 (0–27)

21(5–28)

0.005

Mean length of stay, days (IQR)

12.5 (4–24)

11 (5–20)

−0.04 [−0.35 to 0.27]

0.78

−0.23 [−0.54 to 0.08]

0.14

  1. IMV invasive mechanical ventilation, HFNO high flow nasal canula, IPTW inverse probability of treatment weighting, IQR interquartile